Optional Redemption Due to Changes in Tax Treatment. Each series of Securities may be redeemed at the option of the Issuer (or their successors) in whole but not in part at any time at a Redemption Price equal to the principal amount thereof plus accrued interest to the date fixed for redemption if the Issuer is or would be required to pay Additional Amounts as a result of (i) any change in or amendment to the laws (or any regulations or rulings promulgated thereunder) of the United States or the Netherlands, as the case may be (or in the case of a successor Person to the Issuer, of the jurisdiction in which such successor Person is organized or any political subdivision or taxing authority thereof or therein), or (ii) any change in the official application or interpretation of such laws, regulations or rulings, or any change in the official application or interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which the United States or the Netherlands, as the case may be (or such other jurisdiction or political subdivision or taxing authority), is a party, which change, execution or amendment becomes effective on or after the date of issuance of such series pursuant to Section 301 (or in the case of a successor Person to the Issuer, the date on which such successor Person became such). Prior to the giving of notice of redemption of such Securities pursuant to this Indenture, the Issuer will deliver to the Trustee an Officer’s Certificate, stating that the Issuer is entitled to effect such redemption and setting forth in reasonable detail a statement of circumstances showing that the conditions precedent to the right of the Issuer to redeem such Securities pursuant to this Section have been satisfied.
Appears in 3 contracts
Sources: Indenture Agreement (American Medical Systems Europe B.V.), Indenture (Boston Scientific Corp), Indenture Agreement (American Medical Systems Europe B.V.)